Background: Galcanezumab is approved in the European Union (EU) as migraine prophylaxis in adults with at least four migraine days per month. The aim of this retrospective observational study was to evaluate the long-term effectiveness of galcanezumab on migraine-related burdens and its impact on the use of healthcare resources for migraine prophylaxis in an Italian setting.
Methods: This retrospective study was conducted in patients with migraine who initiated treatment with galcanezumab for migraine prevention between September 2019 and December 2020. Patient data for monthly migraine days (MMDs) and MMDs with acute medication intake were obtained by medical chart reviews. Information on patient-reported outcomes (using the Migraine Disability Assessment [MIDAS] questionnaire and Headache Impact Test 6 [HIT-6] questionnaire) and on the use of healthcare resources were also collected. The time points of interest were 1, 3, 6, 9, 12 months after the initiation of galcanezumab, and the most recent time point available during follow-up.
Results: A total of 207 patients were enrolled in the study. Starting from month 3 after treatment initiation, more than half of the patients presented at least a 50% reduction in MMDs, and approximately one-third of non-responders at month 3 became responders at month 6. From month 3 to month 12, MMDs decreased on average by 10 days. Headache impact and disability, as well as migraine-associated health resource utilization decreased significantly during the treatment period. A positive significant association among the three dimensions of clinical burden (MMDs, MIDAS and days of acute medication intake) was also observed.
Conclusion: The results of this Italian real-world study confirmed that galcanezumab has a rapid onset of effect and provides a long-term response among patients over different migraine-related burdens. The use of healthcare resources was also remarkably reduced.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10951161 | PMC |
| http://dx.doi.org/10.1007/s40120-024-00582-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A 4-Week Mobile App-Based Telerehabilitation Program vs Conventional In-Person Rehabilitation in Older Adults With Sarcopenia: Randomized Controlled Trial.
J Med Internet Res
January 2025
Department of Rehabilitation Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Background: Sarcopenia is closely associated with a poor quality of life and mortality, and its prevention and treatment represent a critical area of research. Resistance training is an effective treatment for older adults with sarcopenia. However, they often face challenges when receiving traditional rehabilitation treatments at hospitals.
View Article and Find Full Text PDFA Comparison of Prostate Cancer Screening Information Quality on Standard and Advanced Versions of ChatGPT, Google Gemini, and Microsoft Copilot: A Cross-Sectional Study.
Am J Health Promot
January 2025
College of Social Work, University of South Carolina, Columbia, SC, USA.
Purpose: Artificially Intelligent (AI) chatbots have the potential to produce information to support shared prostate cancer (PrCA) decision-making. Therefore, our purpose was to evaluate and compare the accuracy, completeness, readability, and credibility of responses from standard and advanced versions of popular chatbots: ChatGPT-3.5, ChatGPT-4.
View Article and Find Full Text PDFDemographics and regional trends of ischemic heart disease-related mortality in older adults in the United States, 1999-2020.
PLoS One
January 2025
Nursing & Midwifery Research Department (NMRD), Hamad Medical Corporation, Doha, Qatar.
Background: Ischemic heart disease (IHD) has a significant impact on public health and healthcare expenditures in the United States (US).
Methods: We used data from the CDC WONDER database from 1999-2020 to identify trends in the IHD-related mortality of patients ≥ 75 years in the US. AAMRs per 100,000 population and APC were calculated and categorized by year, sex, race, and geographic divisions.
Spatial-temporal evolution of the allometric relationship between urban economic and health resources in the Yangtze River Delta urban agglomeration.
PLoS One
January 2025
School of Pharmaceutical Economics and Management, Anhui University of Traditional Chinese Medicine, Hefei, Anhui, China.
The evolution of the spatiotemporal relationship between urban economic growth and health resources within the Yangtze River Delta urban agglomeration provides an important context for understanding the regional development dynamics in China. Previous studies focused on equity in health-resource allocation and service efficiency, often overlooking the allometric growth relationships between health resources and economic variables. This study employs an allometric growth model to elucidate the changing interactions between the number of medical beds, doctors, and urban economic indicators in the Yangtze River Delta region from 2009 to 2022.
View Article and Find Full Text PDFKnowledge, attitudes, and practices (KAP) of animal health staff and farmers towards brucellosis control in sheep and goat in China: A cross-sectional study.
PLoS One
January 2025
Faculty of Veterinary Science, Department of Veterinary Public Health, Chulalongkorn University, Bangkok, Thailand.
Background: In China, brucellosis has resurfaced recently with a discernible spatial distribution, particularly affecting dairy herds and small ruminant populations. However, limited dissemination of knowledge, attitudes, and practices (KAP) for brucellosis control exists among farmers and animal health staff. This study aimed to assess the KAP of brucellosis control and prevention in animal health staff and farmers, with the goal of educating the public regarding the application of efficient brucellosis control and prevention strategies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!